Evidence map›Paper›PMID 39283575›Full record

ArticleAnnals of surgical oncology2024

Evaluation of AJCC Nodal Staging for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Ductal Adenocarcinoma.

Joseph R Habib, Ingmar F Rompen, Ammar A Javed, Anthony M Sorrentino, Mansour E Riachi, Wenqing Cao, Marc G Besselink, I Quintus Molenaar, Jin He, Christopher L Wolfgang and 1 more

Abstract readMulticenter Study
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joseph R HabibDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Ingmar F RompenDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Ammar A JavedDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Anthony M SorrentinoDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Mansour E RiachiDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Wenqing CaoDepartment of Pathology, New York University Langone Health, New York, NY, USA.
Marc G BesselinkDepartment of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
I Quintus MolenaarDepartment of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center and St. Antonius Hospital Nieuwegein, Utrecht, The Netherlands.
Jin HeDepartment of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Christopher L WolfgangDepartment of Surgery, New York University Langone Health, New York, NY, USA.
Lois A DaamenDepartment of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center and St. Antonius Hospital Nieuwegein, Utrecht, The Netherlands. L.A.Daamen-3@umcutrecht.nl.

Funding

Ben and Rose Cole PRIA Foundation NIH T32
6 · The paper itself

Abstract

backgroundThe American Joint Committee on Cancer (AJCC) eighth edition is based on pancreatic intraepithelial neoplasia-derived pancreatic ductal adenocarcinoma (PDAC), a biologically distinct entity from intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic cancer. The role of nodal disease and the AJCC's prognostic utility for IPMN-derived pancreatic cancer are unclear. This study aimed to evaluate the prognostic role of nodal disease and the AJCC eighth-edition N-staging for IPMN-derived pancreatic cancer.

methodsUpfront-surgery patients with IPMN-derived PDAC from four centers were stratified according to the AJCC eighth-edition N stage. Disease characteristics were compared using descriptive statistics, and both overall survival (OS) and recurrence-free survival (RFS) were evaluated using log-rank tests. Multivariable Cox regression was performed to determine the prognostic value of N stage for OS, presented as hazard ratios with 95 % confidence intervals (95 % CIs). A lowest p value log-rank statistic was used to derive the optimal cutoff for node-positive disease.

resultsFor 360 patients, advanced N stage was associated with worse T stage, grade, tubular histology, and perineural and lymphovascular invasion (all p < 0.05). The median OS was 98.3 months (95 % CI 82.8-122.0 months) for N0 disease, 27.8 months (95 % CI 24.4-41.7 months) for N1 disease, and 18.1 months (95 % CI 16.2-25.9 months) for N2 disease (p < 0.001). The AJCC N stage was validated and associated with worse OS (N1 [HR 1.64; range, 1.05-2.57], N2 [HR2.42; range, 1.48-3.96]) and RFS (N1 [HR 1.81; range, 1.23-2.68], N2 [HR 3.72; range, 2.40-5.77]). The optimal cutoff for positive nodes was five nodes.

conclusionThe AJCC eighth-edition N-staging is valid and prognostic for both OS and RFS in IPMN-derived PDAC.

Indexed as

Adenocarcinoma, MucinousCarcinoma, Pancreatic DuctalNeoplasm StagingPancreatic NeoplasmsAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansLymphatic MetastasisLymph NodesMaleMiddle AgedNeoplasm InvasivenessPancreatic Intraductal Neoplasms

Identifiers

PMID39283575
PMCPMC11549140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.